Elevated sEH levels have been observed in multiple neurological disorders including depression, Parkinson’s disease and AD and blocking of sEH activity has been shown to provide therapeutic benefit in related disease models [14, 16, 23, 25, 46–48]. Here, EPHX2 is linked to Alzheimer disease.